Otsuka Establishes Australian Ops

Otsuka Pharmaceutical Co. Ltd., based in Japan, has established a presence in Australia with a new office in Sydney as part of an effort to build a larger, long-term presence in Australia and Oceania. These regions have been experiencing single-digit percentage growth in the past several years and were estimated at approximately $13 billion in 2012.

Otsuka focuses on the development of new drugs for central nervous system disorders such as schizophrenia, depression and Alzheimer’s disease, areas where patients in Australia and elsewhere need better treatments.

Otsuka Australia Pharmaceutical’s recently appointed managing director Kazushi Takemoto, said, “Otsuka is pleased and honored to be a participant in the Australian healthcare sector. We will strive to make a positive contribution with our products in areas of critical, unmet patient need. Our opening in Australia, which is Otsuka’s 27^thaffiliate outside Japan, is an important milestone for Otsuka as the company continues to expand and fulfill its aim to help ease the burden of diseases on people around the globe.”